Bristol-Myers Squibb To Present Data At 2015 ASCO Annual Meeting That Demonstrate The Promise Of Its Broad Immuno-Oncology Portfolio Across Solid Tumors And Blood Cancers Including Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced new clinical research from three of its Immuno-Oncology agents will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 29-June 2. Building on the scientific advances the company has pioneered in Immuno-Oncology, Bristol-Myers Squibb will present data for Opdivo and Yervoy across multiple solid tumor types, as well as elotuzumab in relapsed or refractory multiple myeloma.

Help employers find you! Check out all the jobs and post your resume.